The potential of TB treatment 8 weeks

Published Date: 08 Mar 2023

While some say this strategy's failure rate is "too high," it's one step closer to the "white grail" of a shorter 24-week formula.

Read Full News

Latest News

Africa CDC Cites Concerns Over Data Sharing in US Health Deals

There are big issues in health funding deals the US is pursuing with African countries, the head of the African CDC said Thursday.

U.S. Surgeon General Nominee Means Says She Backs Vaccines, With Parental Conversations

Casey Means, President ⁠Donald Trump's nominee for U.S. ⁠surgeon general and an ally of ⁠Health Secretary ‌Robert F. Kennedy Jr., said before the Senate's Health, Education,...

South Carolina Measles Cases Easing Earlier Than Expected, Health Official Says

South Carolina has reported a drop in measles cases over the past ⁠two weeks, an encouraging sign that the outbreak may be easing earlier than anticipated, a state health...

FDA Vaccine Advisers to Meet in March on Flu Strain Selection

The U.S. Food and Drug Administration said on Wednesday ⁠its advisory committee is set to meet on March 12 to ⁠discuss and make recommendations on the strain composition of...

Gilead's Experimental HIV Treatment Shows Low Discontinuation Rates in Studies

Gilead Sciences on Wednesday said its experimental single-tablet HIV treatment was ⁠generally well tolerated with low discontinuation rates, positioning the single-tablet...

CROI 2026

Read clinically focused news coverage of key developments from CROI 2026.

Todays Updates

Immunotherapy Remains Little Used in Head and Neck Cancer

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

EVP Beats Cisplatin for Resectable MIBC

As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Todays Updates

Immunotherapy Remains Little Used in Head and Neck Cancer

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

EVP Beats Cisplatin for Resectable MIBC

As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Latest News

There are big issues in health funding deals the US is pursuing with African countries, the head of the African CDC said Thursday.

Casey Means, President ⁠Donald Trump's nominee for U.S. ⁠surgeon general and an ally of ⁠Health Secretary ‌Robert F. Kennedy Jr., said before the Senate's Health, Education,...

South Carolina has reported a drop in measles cases over the past ⁠two weeks, an encouraging sign that the outbreak may be easing earlier than anticipated, a state health...

The U.S. Food and Drug Administration said on Wednesday ⁠its advisory committee is set to meet on March 12 to ⁠discuss and make recommendations on the strain composition of...

Gilead Sciences on Wednesday said its experimental single-tablet HIV treatment was ⁠generally well tolerated with low discontinuation rates, positioning the single-tablet...

Read clinically focused news coverage of key developments from CROI 2026.

News All Time

Next-Day HIV Test Result Show Mixed Effects on Seeking Care

Next-day HIV viral load test results do not improve overall linkage to care when added to standard testing but are tied to faster linkage to antiretroviral therapy among people with HIV infection.

Cancer Screening Gaps Leave People With HIV at Elevated Risk

International guidelines recommend anal and liver surveillance for people with HIV, but Brazil lacks a national protocol; clinicians should integrate screening and vaccination.

ED Screening Uncovers Elevated Risk for Cervical Cancer

Emergency department-based cervical cancer interventions identify precancerous lesions and high-risk human papillomavirus at rates higher than the national average, a study shows.

Pritelivir Shows Promise for HSV

The new oral therapy demonstrates superior lesion healing for complex patients who have few current treatment options.

STI Prevention With Doxycycline Raises Resistance Fears

Public health authorities warn clinicians to weigh risks and enroll patients in supervised programs: routine testing, partner management, and resistance surveillance are essential.

AAS Misuse Damages Heart, Liver, Kidneys, and Brain

Supraphysiologic anabolic steroid use is increasing among recreational athletes, causing cardiac, psychiatric, renal, and reproductive complications.

Gaps in Primary Care Affect Transgender Health in Spain

Data from more than 1800 participants outlines structural barriers, high mental health diagnoses, and uneven access to gender-affirming and preventive services.

Use of Opioid Combinations Tied to Impaired Cognition in HIV

The use of opioids alone does not significantly impair cognition in patients with HIV infection, but the combined use of opioids and antidepressants is linked to poorer neurocognitive performance.

Zimbabwe Rolls Out New HIV Prevention Drug Lenacapavir

Zimbabwe's health authorities begin administering the long-acting HIV prevention drug lenacapavir, making ⁠the country one of the first globally to roll it out.

Four States and New York City Join WHO Outbreak Network

After United States’ withdrawal from the WHO, four states and New York City have partnered with the WHO to maintain access to international outbreak intelligence and strengthen preparedness efforts.

Medicaid expansion increases access to HIV prevention medication for high-risk populations

Medicaid expansion under the Affordable Care Act (ACA) significantly increased the number of people at risk of HIV diagnosis who were prescribed preexposure prophylaxis (PrEP), a preventative medication taken in pill or injectable ...

Keto diet stops a young girl's epileptic seizures

Alana "Lani" Silverberg was a real firecracker with a big personality at age 3—until she started having seizures.

Trial evaluates a vitamin B3 derivative in people with long COVID

Millions of people worldwide continue to experience lingering symptoms after COVID-19, a condition known as long COVID. These symptoms can affect people of all ages and often include neurological issues such as "brain fog," ...

High disease burden found among at-risk Medicaid beneficiaries

Over 40% of the 5 million people at risk of losing Medicaid coverage due to new eligibility requirements have at least three chronic health conditions, and older adults are especially vulnerable, a new JAMA study shows.

Pneumocystis pneumonia is striking unexpected patient groups, study shows

A seven-year study of 470 patients revealed that a severe fungal lung infection once mainly seen in specific high-risk groups is increasingly affecting elderly patients and those with common cancers who are not receiving ...

Ethiopia confirms 3 Marburg virus deaths in new outbreak

Ethiopia on Monday confirmed three deaths from the Marburg hemorrhagic virus that has been detected in an area neighboring South Sudan.

Recommended News For You

Research indicates that extended PSMA therapy is safe and effective for patients with prostate cancer.

Progress in Early Cancer Diagnosis; Breast Cancer in Younger Women; Diet and Cancer.

unhealthy sleeping habits and the risk of esophageal adenocarcinoma.

ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer

Mezigdomide Combinations Show Promise in Multiple Myeloma

More nonsmokers are getting lung cancer: Oncologist explains why

The most precise research tools for the deadliest blood cancer have been developed.

Recommended Articles For You

Unlocking the Potential of Hemin: A Novel Approach to Health and Wellbeing 

The latest research on Thyroid Cancer: Symptoms, Diagnosis, and Treatment Options  

Future-Ready Cancer Screening: What Every Clinician Should Know in 2025 

What You Need to Know about Hairy Cell Leukemia: A Comprehensive Guide  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study indicates that exercise can help colon cancer survivors live as long as matched individuals

2.

A new theranostic drug targets different cancer types.

3.

Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma

4.

Investigations may result in novel combination therapies for early-stage lung cancers.

5.

A better option for mild to moderate depression?

1.

KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer

2.

Claudin-18.2 in Gastric Cancer: Tumor-Stroma Crosstalk and Disease Progression

3.

Advancements in Cancer Treatment Strategies for Non-Hodgkin Lymphoma

4.

Ear Emergency: Understanding the Causes and Treatment for Auricular Hematoma

5.

Mastering Breast Cancer Care in 2025: Diagnosis, Treatment, Education, and Innovation

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Navigating the Complexities of Ph Negative ALL - Part XVI

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II

3.

"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC

4.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II

5.

The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot